Answers are grounded in this paper and cite their sources.
// Tsion Zewdu Minas 1, * , Jenny Han 1, * , Tahereh Javaheri 3 , Sung-Hyeok Hong 1 , Michaela Schlederer 3, 4 , Yasemin Saygideğer-Kont 1 , Haydar Çelik 1 , Kristina M. Mueller 8 , Idil Temel 1 , Metin Özdemirli 2 , Heinrich Kovar 7, 9 , Hayriye Verda Erkizan 1 , Jeffrey Toretsky 1 , Lukas Kenner 3, 4, 5 , Richard Moriggl 3, 6, 8 , Aykut Üren 1 1 Department of Oncology, Georgetown University Medical Center, Washington, DC, USA 2 Department of Pathology, Georgetown University Medical Center, Washington, DC, USA 3 Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria 4 Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria 5 Unit of Pathology of Laboratory Animals, University of Veterinary Medicine, Vienna, Austria 6 Medical University of Vienna, Vienna, Austria 7 Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria 8 Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria 9 Department of Pediatrics, Medical University of Vienna, Vienna, Austria * These authors have contributed equally to this work Correspondence to: Aykut Üren, e-mail: au26@georgetown.edu Keywords: EWS-FLI1, ETS fusion proteins, YK-4-279, ewing sarcoma, erythoid leukemia Received: June 11, 2015 Accepted: September 28, 2015 Published: October 08, 2015 ABSTRACT Ewing sarcoma is an aggressive tumor of bone and soft tissue affecting predominantly children and young adults. Tumor-specific chromosomal translocations create EWS-FLI1 and similar aberrant ETS fusion proteins that drive sarcoma development in patients. ETS family fusion proteins and over-expressed ETS proteins are also found in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. Transgenic expression of EWS-FLI1 in mice promotes high penetrance erythroid leukemia with dense hepatic and splenic infiltrations. We identified a small molecule, YK-4-279, that directly binds to EWS-FLI1 and inhibits its oncogenic activity in Ewing sarcoma cell lines and xenograft mouse models. Herein, we tested in vivo therapeutic efficacy and potential side effects of YK-4-279 in the transgenic mouse model with EWS-FLI1 induced leukemia. A two-week course of treatment with YK-4-279 significantly reduced white blood cell count, nucleated erythroblasts in the peripheral blood, splenomegaly, and hepatomegaly of erythroleukemic mice. YK-4-279 inhibited EWS-FLI1 target gene expression in neoplastic cells. Treated animals showed significantly better overall survival compared to control mice that rapidly succumbed to leukemia. YK-4-279 treated mice did not show overt toxicity in liver, spleen, or bone marrow. In conclusion, this in vivo study highlights the efficacy of YK-4-279 to treat EWS-FLI1 expressing neoplasms and support its therapeutic potential for patients with Ewing sarcoma and other ETS-driven malignancies.
No takes yet. Share an insight, caveat, or question.
Minas et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: